Background: Given the rarity of esthesioneuroblastoma, it is difficult to validate a staging system.
| I N TR ODU C TI ON
Esthesioneuroblastoma, also known as olfactory neuroblastoma, is a rare cancer thought to arise from neuroendocrine cells in the olfactory epithelium. Esthesioneuroblastoma represents about 3%-6% of all cancers in the nasal cavity and paranasal sinuses, although incidence has been hard to determine because of its uncommon nature. 1 Epidemiological numbers may have skewed by past inclusion of sinonasal undifferentiated carcinoma and sinonasal neuroendocrine carcinoma before advent of more accurate histological techniques. 2 There are a number of staging systems used for esthesioneuroblastoma. Given the rarity of esthesioneuroblastoma, it is difficult to validate a staging system. The most commonly used staging system is the Kadish staging system. Kadish staging was first introduced in 1976
as the staging method before treatment based on the extension of disease. 3, 4 Alternate staging systems have been proposed by Dulguerov and Calcaterra 5 and Biller et al, 6 which use different definitions of disease extent. Previous studies found that the modified Kadish staging system could be a useful predictor in survival. 1, 2 However, in other studies, Kadish staging was not identified as a prognostic factor. 5, 7 Further evaluation of the value of the modified Kadish staging in esthesioneuroblastoma is warranted.
A previous analysis of esthesioneuroblastoma was done by survival. Overall survival at 10 years was 83.4% for patients with stage A disease, 49% for patients with stage B disease, 38.6% with stage C disease, and 13.3% for patients with stage D disease. Combined treatment with surgery and radiotherapy (RT) was also found to have greater statistically significant median survival (216.8 months) than RT alone (53.7 months). 8 The SEER database compiles data on cancer diagnoses and outcomes from population-based cancer registries that cover 28% of the US population. In contrast, the data in National Cancer Database (NCDB) is identified from the hospitals and captures over 70% of all incident cancers in the United States. It includes more detailed information on tumor characteristics, surgery, RT, and chemotherapy when compared to the SEER database, which is very useful when evaluating a surgically based staging system. This allows for more in-depth study of tumor characteristics, treatment trends, and their influence on survival outcomes.
In this investigation, we sought to analyze the prognostic value of Kadish staging using the NCDB for outcomes related to esthesioneuroblastoma.
| M A TE RI A L S A ND M E TH ODS

| Data source
The NCDB is a national hospital-based cancer registry sponsored by the American College of Surgeon's Commission on Cancer and the American Cancer Society. As previously noted, it includes approximately 70% of newly diagnosed cancer cases in the United States from over 1500 accredited cancer care programs. The database provides extensive information on patient demographics, extent of disease, and treatment regimens, as well as long-term overall survival.
| Patient population
Patients diagnosed as having olfactory neuroblastoma of the nasal cavity and paranasal sinuses between January 1, 2004, and December 31, 2013, were identified. Given the deidentified nature of patient data, the analysis was exempt from review by our institutional review board. The NCDB was queried for olfactory neuroblastoma cases using 
| Statistical analysis
All statistical analyses were performed using the SAS software package 
| R ESU L TS
Of the cohort, 1167 patients met inclusion criteria. Patient demographics, disease characteristics, and treatment factors are listed in years). Men represented 60.5% of the patients, whereas women represented 39.5% of the patients. White patients accounted for the majority of cases (84.0%). Of the patients, 64.1% were treated at academic centers, whereas 36.0% were treated at nonacademic centers. Over 50% of the patients had Kadish stage C disease.
| Staging
Survival for the 1107 patients with Kadish staging is presented in 
| Treatment modalities
In the whole cohort, there was no difference in 5-year overall survival between the surgery and surgery with adjuvant radiation groups 
| Prognostic factors and multivariate analysis
Age less than 60 years, female sex, having private insurance, and negative margins after surgery were associated with improved survival on univariate analysis when compared to age greater than 60 years, male sex, having government insurance, and positive margin status, respectively (Table 2) .
Multivariate analysis was done using demographic variables and treatment variables. Age and insurance status were correlated as were the type of treatment and margin status, and were included as they were deemed to be clinically important. Results showed that age less than 60 years (HR 0.47 [confidence interval (CI) 0.28-0.79]) and negative margins Table 2 ). Sex, which was associated with survival during the univariate analysis, was not independently associated with survival on multivariate analysis.
| D I SCUSSION
Esthesioneuroblastoma represents approximately 5% of all malignant sinonasal tumors. Because of its rarity, much of the available literature available is comprised of smaller retrospective institutional studies. In this cohort, 5-year overall survival was 77.4%, which is comparable to previous retrospective studies that had survival rates from 62.1%-89%. 1, 9, 10 There is no standardized staging system for esthesioneuroblastoma as it is difficult to determine the prognostic ability of each A meta-analysis found that Kadish staging predicted survival unless considered in conjunction with Hyams grade, when it was no longer predictive. However, Hyams grade was independently predictive of survival, with higher grade indicating worse survival. 15 As Hyams grade requires surgical biopsy, it is more difficult to obtain. However, as the study found that 14% of Kadish A tumors were of high Hyams grade, it may be important to determine histological grade for more accurate prediction. 15 Other staging systems have also been shown to be predictors of survival in a limited number of studies. In the original study in which the Dulguerov TNM classification was proposed, it was found to be a better predictor of survival than the Billings and Kadish staging. | 1967
